Olumiant (baricitinib) - Eli Lilly
Efficacy and Safety of Baricitinib in Refractory Juvenile Dermatomyositis: A Retrospective Study. (PubMed, Am J Ther) - Aug 29, 2026 - No abstract available 
Journal • Retrospective data • Dermatomyositis • Immunology • Myositis
http://www.ncbi.nlm.nih.gov/pubmed/42661254
 
Bin Zhang; Qi He; Qin Hu; Qing-Chun Diao; Shi Yan; Yu-Ting Gan
 
Aug 29, 2026
 
Prev Next